Related Experiment Videos
[Hemolytic anemia associated with breast neoplasm]
V Ferrari1, S Bertuol, A Battaglia
1Divisione di Medicina Generale, Azienda Ospedaliera Ospedale di Circolo e Fondazione Macchi, Ospedale F. Del Ponte, Varese.
Recenti Progressi in Medicina
|November 7, 2001
Summary
This case study highlights a rare complication of advanced breast cancer: microangiopathic hemolytic anemia (MHA) with thrombocytopenia. Chemotherapy led to partial remission of MHA, improving the patient's prognosis.
Area of Science:
- Oncology
- Hematology
- Pathology
Background:
- Microangiopathic hemolytic anemia (MHA) is a rare but serious complication associated with advanced malignant neoplasms.
- Breast and gastric carcinomas are particularly linked to the development of MHA.
- MHA in the context of cancer carries a grave prognosis, with limited survival in untreated patients.
Observation:
- A patient presented with microangiopathic hemolytic anemia (MHA) and thrombocytopenia.
- The patient's condition was a consequence of breast cancer in an advanced stage.
- This presentation underscores the significant hematological impact of advanced malignancies.
Findings:
- The patient received chemotherapy for advanced breast cancer.
- Treatment resulted in a partial remission of the microangiopathic hemolytic anemia.
- A notable reduction in the need for blood transfusions was observed post-chemotherapy.
Implications:
- This case demonstrates that chemotherapy can induce partial remission in MHA associated with advanced breast cancer.
- Early recognition and treatment of MHA in cancer patients may improve outcomes and reduce transfusion dependency.
- Further research into the mechanisms and management of cancer-associated MHA is warranted.